Clinical evaluation of serum levels of CA-125 in patients with digestive diseases.

概要

論文の詳細を見る
In order to evaluate the usefulness of CA-125 in patients with digestive diseases, serum levels of the antigen were determined in 455 patients with various malignancies and 303 patients with benign diseases.Elevated srum CA-125 levels (_??_35U/ml) were observed in 66% of pancreatic cancers, 51% of hepatocellular cancers and 47% of biliary tract cancers in order of frequency. Among the pancreatic cancers studied, CA-125 were positive in 7 of the 14 CA 19-9 negative patients (<37U/ml), 24 of the 37 DU-PAN-2 negative patients (<400U/ml) and 13 of the 28 CEA negative patients (<2.5ng/ml). Almost all of the positive cases among the stomach and colon cancers were founded in more than stage IV or inoperable patients. Especially in patients with peritoneal metastasis, the incidence of CA-125 was significantly higher than those of the other markers. It is suggested that CA-125 elevation reflects the peritoneal metastasis. On the other hand, the false-positive rate was low in benign disease. However, high levels of CA-125 were observed in almost all cases of decompensated liver cirrhosis, fulminant hepatitis and severe acute pancreatitis with ascites. Changes of the antigen correlated with progression or regression of ascites.The assay of serum CA-125 is considered to be useful not only in diagnosis of patients with digestive cancers, espcially pancreatobiliary cancer but also in evaluation of ascites formation or peritoneal involvement.
財団法人日本消化器病学会の論文

Clinical evaluation of serum levels of CA-125 in patients with digestive diseases.

スポンサーリンク

概要

著者

関連論文

スポンサーリンク